What is the latest FORTIS stock price?
The latest stored price for FORTIS is Rs 907.10 as of 2026-08-21.
gimli
FORTIS stock AI analysis
FORTIS Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
FORTIS HEALTHCARE LTD is a mid-cap stock in Healthcare. This Gimli page shows the latest available FORTIS price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹907.10
1W return
-2.36%
1M return
-6.39%
3M return
-6.22%
6M return
-1.51%
1Y return
-4.27%
Market cap
₹68,482.25 cr
PE
82.58
PB
6.73
ROE
+8.58%
ROCE
+13.48%
RSI
41.49
Turnover
₹73.72 cr
Why it can matter in screens
- Momentum: FORTIS is below 50DMA, below 200DMA; RSI is 41.49.
- Returns: 1D -1.06%, 1W -2.36%, 1M -6.39%, 3M -6.22%, 1Y -4.27%.
- Trend levels: 52W high ₹1,010.10, 52W low ₹879.10, off high -10.20%.
- Liquidity: latest turnover is ₹73.72 cr; volume vs 20D is +0.52%.
- Valuation/profitability: PE 82.58, PB 6.73, ROE +8.58%, ROCE +13.48%.
- Growth: 3Y sales CAGR +13.68%, 3Y profit CAGR +20.95%.
Quick Answers
Is FORTIS above its 50DMA and 200DMA?
FORTIS is below 50DMA, below 200DMA. The latest 50DMA is 949.61 and the latest 200DMA is 918.02.
What are FORTIS PE, ROE and ROCE?
FORTIS has PE 82.58, ROE +8.58%, and ROCE +13.48% in Gimli's latest available snapshot.
How has FORTIS performed recently?
FORTIS has returned -6.39% over 1 month, -6.22% over 3 months, and -4.27% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 508.37 cr | 122.85 cr | 47.78 cr | 3.53 |
| 2026-03-31 | 2,364.67 cr | 530.45 cr | 265.85 cr | 3.52 |
| 2025-12-31 | 2,265.01 cr | 471.56 cr | 193.73 cr | 2.57 |
| 2025-09-30 | 2,331.44 cr | 606.12 cr | 321.92 cr | 4.26 |
| 2025-06-30 | 2,166.72 cr | 521.62 cr | 260.28 cr | 3.45 |
| 2025-03-31 | 2,007.20 cr | 406.34 cr | 183.89 cr | 2.44 |
| 2024-12-31 | 1,928.26 cr | 421.87 cr | n/a | nan |
| 2024-09-30 | 1,988.39 cr | 392.53 cr | n/a | 2.34 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 9,127.84 cr | 2,129.75 cr | 1,041.78 cr | 3.05 |
| 2025-03-31 | 7,782.75 cr | 1,577.06 cr | 774.21 cr | 10.26 |
| 2024-03-31 | 6,835.09 cr | 1,308.51 cr | 598.88 cr | 7.93 |
| 2023-03-31 | 6,213.15 cr | 1,237.80 cr | 588.73 cr | 7.80 |
| 2022-03-31 | 996.71 cr | 1,415.90 cr | -13.25 cr | 7.35 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 15,966.23 cr | 406.97 cr | 3,472.58 cr | 10,168.51 cr |
| 2025-03-31 | 13,691.53 cr | 139.72 cr | 2,475.11 cr | 9,169.39 cr |
| 2024-03-31 | 13,288.78 cr | 235.27 cr | 1,155.02 cr | 8,556.14 cr |
| 2023-03-31 | 12,433.60 cr | 141.08 cr | 925.72 cr | 8,100.39 cr |
| 2022-03-31 | 11,884.75 cr | 143.23 cr | 1,254.93 cr | 7,008.25 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 1,601.46 cr | 656.02 cr | n/a |
| 2025-03-31 | 1,423.93 cr | 577.00 cr | n/a |
| 2024-03-31 | 1,100.10 cr | 157.63 cr | n/a |
| 2023-03-31 | 822.25 cr | 375.01 cr | n/a |
| 2022-03-31 | 865.39 cr | 649.90 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +31.17% | +25.20% | +32.23% | +25.81% | +11.40% | +0.00% |
| 2026-03-31 | +31.17% | +25.97% | +31.35% | +25.72% | +11.51% | +0.00% |
| 2025-12-31 | +31.17% | +27.84% | +29.33% | +24.22% | +11.67% | +0.00% |
| 2025-09-30 | +31.17% | +27.90% | +29.14% | +24.92% | +11.79% | +0.00% |
| 2025-06-30 | +31.17% | +27.17% | +29.79% | +26.07% | +11.87% | +0.00% |
| 2025-03-31 | +31.17% | +27.40% | +29.46% | +25.77% | +11.97% | +0.00% |
| 2024-12-31 | +31.17% | +26.77% | +30.05% | +26.66% | +12.01% | +0.00% |
| 2024-09-30 | +31.17% | +25.26% | +30.73% | +27.23% | +12.84% | +0.00% |
| 2024-06-30 | +31.17% | +23.31% | +32.31% | +27.52% | +13.21% | +0.00% |
| 2024-03-31 | +31.17% | +23.24% | +31.15% | +26.51% | +14.45% | +0.00% |
| 2023-12-31 | +31.17% | +23.71% | +29.41% | +25.04% | +15.71% | +0.00% |
| 2023-09-30 | +31.17% | +26.31% | +26.55% | +22.50% | +15.97% | n/a |
| 2023-06-30 | +31.17% | +30.03% | +22.16% | +18.49% | +16.64% | +0.00% |
| 2023-03-31 | +31.17% | +31.22% | +20.70% | +17.38% | +16.92% | +0.00% |
| 2022-12-31 | +31.17% | +31.01% | +20.38% | +17.50% | +17.44% | +0.00% |
| 2022-09-30 | +31.17% | +30.59% | +20.03% | +16.89% | +18.22% | n/a |
| 2022-06-30 | +31.17% | +0.00% | +47.26% | n/a | n/a | +0.00% |
| 2022-03-31 | +31.17% | +0.00% | +46.72% | n/a | n/a | +0.00% |
| 2021-12-31 | +31.17% | +0.00% | +45.75% | n/a | n/a | +0.00% |
| 2021-09-30 | +31.17% | +0.00% | +45.12% | n/a | n/a | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 456,449.49 cr | 37.677543 | +15.50% | +15.99% |
| DIVISLAB | DIVI S LABORATORIES LTD | 228,223.36 cr | 78.319614 | +18.37% | +42.62% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 165,719.79 cr | 75.983398 | +17.33% | +34.25% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 124,992.04 cr | 63.823550 | +21.03% | +9.67% |
| CIPLA | CIPLA LTD | 115,693.19 cr | 34.304976 | +10.25% | -10.08% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 112,698.21 cr | 22.474914 | +17.93% | +13.61% |
| LUPIN | LUPIN LIMITED | 100,669.80 cr | 14.727517 | +34.34% | +12.19% |
| MANKIND | MANKIND PHARMA LIMITED | 98,418.27 cr | 47.977550 | +13.18% | -8.31% |
Try these prompts
- Analyze FORTIS HEALTHCARE with valuation, momentum and industry peers
- Compare FORTIS with other Healthcare stocks
- Show mid-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View mid-cap stocks
- Find stocks above 50DMA
- Compare FORTIS with other Healthcare stocks
Data snapshot: 2026-08-21. Not investment advice.